Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy (Q42442672)

31 October 2017

Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy (English)

1 reference

31 October 2017

Limas CJ

1

1 reference

31 October 2017

Hasikidis C

2

1 reference

31 October 2017

Iakovou J

3

1 reference

31 October 2017

Kroupis C

4

1 reference

31 October 2017

Haidaroglou A

5

1 reference

31 October 2017

Cokkinos DV

6

1 reference

31 October 2017

1 June 2003

1 reference

European Journal of Clinical Investigation

31 October 2017

1 reference

31 October 2017

33

1 reference

31 October 2017

443-448

1 reference

31 October 2017

6

1 reference

Phenotypic patterns of mononuclear cells in dilated cardiomyopathy.

31 October 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2003.01111.X

Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2003.01111.X

Interleukin 2 and its receptors: recent advances and new immunological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2003.01111.X

T-lymphocyte subsets as noninvasive markers of cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2003.01111.X

Effect of prolonged catecholamine infusion on immunoregulatory function: implications in congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2003.01111.X

Lack of T cell response to cardiac myosin and a reduced response to PPD in patients with idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2003.01111.X

A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2003.01111.X

HLA Class II-associated polymorphism of interferon-γ production implications for HLA-disease association

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2003.01111.X

Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2003.01111.X

Cytokines and cardiac contractile function

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2003.01111.X

Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Correlation with disease severity and cardiac autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2003.01111.X

Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2003.01111.X

Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2003.01111.X

Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2003.01111.X

10.1046/J.1365-2362.2003.01111.X

21 January 2018

Identifiers

DOI

1 reference

31 October 2017

1 reference